Just closed an angel round, 10/10 would recommend.

From Zero to Angel: Lessons from Closing an Angel Round

I began my career as a medical scientist in academia, with no natural inclination toward entrepreneurship. After a period of pursuing research, I chose to start a company when compelling results emerged. For several years, I walked the traditional startup path—the post-its, customer canvases, and pitch decks—while living on savings, side gigs, and my partner’s wages.

We eventually brought a few people on board, joined an excellent incubator for a year, and met hundreds of venture capitalists. Despite many VC meetings, we didn’t secure institutional investment—“you’re too early,” they’d say. Yet, just months after beginning conversations with angel investors, we reached a turning point: 3 million in the bank. Angels proved to be more accessible once they connected with passion for the work; when they see conviction and potential, you’re already halfway there.

Years of uncertainty and grit culminated in the relief of two crucial outcomes: steady cash to pay wages and a network of about ten angels with relevant domain experience in our corner. It felt like pushing to the edge of our limits, only to reach a sizable, welcoming reservoir of support.

If I could do it all again, I’d place 100% emphasis on product—product—product, and get it into customers’ hands as soon as possible. Crafting the pitch is enjoyable, but save it for when you have a real story to tell. Release the MVP early enough that you’re almost embarrassed by how rough it is, because real users and feedback matter more than polished slides.

Note on the valuation (an important correction): I’m based in Sweden, and the initial figures were misrepresented. The deal valued at 3 million SEK for 15% equity translates to approximately 300,000 USD at a 2 million USD/EUR valuation framework. This misstep is a reminder that European startup funding landscapes can differ significantly from American norms, where some investors may show different preferences. The broader takeaway remains: validate your terms early, understand the implications for your cap table, and be mindful of cross-border expectations—especially if considering aligning with U.S. investors that may require open structures such as a Delaware-registered entity.

Takeaways for founders:
– Focus relentlessly on the product and early customer validation.
– Don’t chase the perfect pitch deck before you have a compelling, testable MVP.
– Angels can be easier to engage when you have clear passion and early traction; treat angel conversations as product storytelling.
– Be precise about valuation and cap table implications, particularly with cross-border funding.
– Build a support network of experienced advisors and investors who can help you navigate growth and governance.

If you’re navigating a similar path, a grounded emphasis on product, customer feedback, and strategic fundraising can turn early traction into a sustainable, investor-ready narrative.